title: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial.
abstract: OBJECTIVE
  To investigate the clinical outcome after intracoronary administration of autologous progenitor cells in patients with acute myocardial infarction (AMI).
  
  
  RESULTS
  Using a double-blind, placebo-controlled multicentre trial design, we randomized 204 patients with successfully reperfused AMI to receive intracoronary infusion of bone-marrow-derived progenitor cells (BMCs) or placebo medium into the infarct artery 3-7 days after successful infarct reperfusion therapy. At 12 months, the pre-specified cumulative endpoint of death, myocardial infarction, or necessity for revascularization was significantly reduced in the BMC group compared with placebo (P=0.009). Likewise, the combined endpoint death, recurrence of myocardial infarction, and rehospitalization for heart failure was significantly (P=0.006) reduced in patients receiving intracoronary BMC administration. Intracoronary administration of BMC remained a significant predictor of a favourable clinical outcome by Cox regression analysis, adjusting for classical predictors of poor outcome after AMI.
  
  
  CONCLUSIONS
  Intracoronary administration of BMCs is associated with a significant reduction of the occurrence of major adverse cardiovascular events after AMI. Large-scale studies are warranted to confirm the effects of BMC administration on mortality and morbidity in patients with AMIs.
authors.affiliation: J. W. Goethe Universität Frankfurt, Med. Klinik III, Abt. Kardiologie, Theodor-Stern-Kai 7, 60590 Frankfurt a. M., Germany.
authors.forename: Volker
authors.initials: V
authors.lastname: Schächinger
authors.forename: Sandra
authors.initials: S
authors.lastname: Erbs
authors.forename: Albrecht
authors.initials: A
authors.lastname: Elsässer
authors.forename: Werner
authors.initials: W
authors.lastname: Haberbosch
authors.forename: Rainer
authors.initials: R
authors.lastname: Hambrecht
authors.forename: Hans
authors.initials: H
authors.lastname: Hölschermann
authors.forename: Jiangtao
authors.initials: J
authors.lastname: Yu
authors.forename: Roberto
authors.initials: R
authors.lastname: Corti
authors.forename: Detlef G
authors.initials: DG
authors.lastname: Mathey
authors.forename: Christian W
authors.initials: CW
authors.lastname: Hamm
authors.forename: Tim
authors.initials: T
authors.lastname: Süselbeck
authors.forename: Nikos
authors.initials: N
authors.lastname: Werner
authors.forename: Jürgen
authors.initials: J
authors.lastname: Haase
authors.forename: Jörg
authors.initials: J
authors.lastname: Neuzner
authors.forename: Alfried
authors.initials: A
authors.lastname: Germing
authors.forename: Bernd
authors.initials: B
authors.lastname: Mark
authors.forename: Birgit
authors.initials: B
authors.lastname: Assmus
authors.forename: Torsten
authors.initials: T
authors.lastname: Tonn
authors.forename: Stefanie
authors.initials: S
authors.lastname: Dimmeler
authors.forename: Andreas M
authors.initials: AM
authors.lastname: Zeiher
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D012008:Recurrence; D016896:Treatment Outcome